Exelixis Inc (NASDAQ:EXEL)
| 21.57 Delayed Data As of Jul 01 |  +0.75 / +3.60%Today’s Change | 15.50 Today|||52-Week Range 23.40 | +18.00% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $6.9B |
Company Description
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Contact Information
Exelixis, Inc. 1851 Harbor Bay Parkway Alameda California 94502 |
Employees
Shareholders
| Mutual fund holders | 50.70% |
| Other institutional | 34.58% |
| Individual stakeholders | 3.32% |
Top Executives
| Michael M. Morrissey | President, Chief Executive Officer & Director |
| Dana T. Aftab | Executive Vice President-Business Operations |
| Christopher J. Senner | Chief Financial Officer & Executive Vice President |
| Peter Lamb | Chief Scientific Officer & EVP-Scientific Strategy |
| Vicki L. Goodman | Chief Medical Officer & Executive Vice President |
